The reality of treating dyslipidaemia in patients with coronary heart disease: A primary case survey

International Journal of Clinical Practice

Volumn 57, Issue 6, 2003, Pages 488-491

  Wright, D J ^a   Grayson, A D ^a   Jackson, M ^a   Dainty, C ^b  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^b Lewisham Medical Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CERIVASTATIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NICORANDIL; NITRATE; PRAVASTATIN; SIMVASTATIN;

ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; EXERCISE TEST; FEMALE; GENERAL PRACTICE; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SECONDARY PREVENTION;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; COHORT STUDIES; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE;

EID: 0042490588     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. BHF statistics database: www.dphpc.ox.ac.uk/bhfhprg/stats/2000/hdex.html
2. National Service Framework for coronary heart disease. Modern standards and service models, 2000. London: Stationery Office, 2000.
3. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 79: 1615-1622.
4. NHS Executive. Standing medical advisory committee on the use of statins. London: Department of Health, 1997.
5. Wood D, Durrington P, Poulter N et al, for the British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80: S1-S29.
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
7. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
8. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
9. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs; evidence from a national cross sectional survey. BMJ 2000; 321: 1322-1325.
10. Brady AJB, Oliver MA, Pittard JB. Secondary prevention in 24,431 patients with coronary heart disease: survey in primary care. BMJ 2001; 322: 1463.
11. EUROASPIRE study group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principle results. Eur Heart J 1997; 18: 1569-1582.
12. Campbell NC, Thain J, Deans HG et al. Secondary prevention in coronary heart disease; baseline survey of provision in general practice. BMJ 1998; 316: 1430-1434.
13. EUROASPIRE II study group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J 2001; 22: 554-572.
14. Pitt B, Waters D, Brown WV et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-76.
15. Schwartz GG, Olsson AC, Ezekowitz MD et al. Effects of atorvastatin on recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomised controlled study. JAMA 2001; 285: 1711-1718.
16. Stein E. Cerivastatin in primary hyperlipidemia: a multi-center analysis of efficacy and safety. Am J Cardiol 1998; 82: 40J-46J.
17. Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 4: 220-228.